TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$115.87
-$4.08(-5.19%)
At close: 4:00 PM EST
$115.87
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)909.75K
Market Cap
$2.18B
Enterprise Value$2.54B
Total Cash (Recent Filing)$461.74M
Total Debt (Recent Filing)$818.75M
Price to Earnings (P/E)116.8
Beta1.10
Next Earnings
Jul 30, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.03
Shares Outstanding34,560,910
10 Day Avg. Volume813,894
30 Day Avg. Volume909,752
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue4.00
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda18.50
Forecast
1Y Price Target
$130.80Price Target Upside12.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)2.15
Revenue Forecast (FY)$732.76M
Bulls Say, Bears Say
Bulls Say
Clinical EvidencePublication of large-scale liver outcomes in high-profile medical journals could strengthen clinical credibility and encourage wider adoption of the company's organ care systems.
International ExpansionRolling out an organ procurement network across multiple European countries could materially expand the addressable market and support sustained device and service revenue growth.
Kidney Program OpportunityAdvancement of a kidney organ care system could become the company's largest organ initiative, substantially increasing transplant volumes and creating meaningful revenue upside.
Bears Say
Heart Transplant Volume WeaknessDeclining heart transplant surgeries reduce demand for a key product application and could pressure segments of the company's revenue.
Organ Management Organization RiskA public proposal to operate an organ management organization could provoke pushback from incumbent organ procurement groups and temporarily disrupt donor volumes and market stability.
Revenue Forecast UncertaintyDivergent results from top-down registry and bottom-up aviation analyses create uncertainty around revenue forecasts and raise the risk of missing market expectations.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $2.18B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Jul 30, 2026 which is in 72 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on May 05, 2026. The company reported $0.3 earnings per share for the quarter, missing the consensus estimate of $0.598 by -$0.298.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.57.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,560,910 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.3 in its last earnings report, missing expectations of $0.598. Following the earnings report the stock price went down -23.186%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$130.80 (12.89% Upside)
$130.80 (12.89% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 92%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.31%
12-Months-Change
Fundamentals
Return on Equity
41.92%
Trailing 12-Months
Asset Growth
71.32%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates solid top-line growth (21% YoY) and a strong cash position (~$462M), supported by clear, multi-year growth initiatives (CHOPS, OCS Kidney Gen 3.0, Gen 3.0 upgrades, and European NOP expansion) and reiterated full‑year guidance (20%–25% revenue growth). Near term, the company is absorbing deliberate, sizeable investments that compress gross and operating margins (gross margin down ~331 bps YoY; adjusted operating expenses up ~42% YoY), while donor-volume volatility and prior competitive-driven enrollment delays create execution and timing risk for clinical programs. Overall the call strikes a positive tone on growth and strategic direction but acknowledges tangible near-term margin and enrollment headwinds.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$130.80
▲(12.89% Upside)
Technical Analysis
Ownership Overview
3.48% Insiders
42.27% Mutual Funds
22.39% Other Institutional Investors
6.06% Public Companies and Individual Investors